

AMENDMENT UNDER 37 C.F.R. § 1.111
U.S. APPLN. NO. 09/530,807

IN THE ABSTRACT OF DISCLOSURE:

The abstract is added on a separate sheet as follows:

Abstract

The present invention relates to a novel receptor, in particular to a new type of receptor with affinity for compounds of the oxazoline class, compounds which bind to this receptor, and the use of these compounds in the treatment of diseases, especially diseases of the central nervous system, the cardiovascular system and the kidney.